Allarity Therapeutics, Inc. (ALLR)
1.262
+0.01
(+0.96%)
USD |
NASDAQ |
Sep 09, 16:00
1.27
+0.01
(+0.63%)
Pre-Market: 20:00
Allarity Therapeutics Debt to Equity Ratio : 6.303 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.303 |
| March 31, 2026 | 3.106 |
| December 31, 2025 | 0.1425 |
| September 30, 2025 | 0.1157 |
| June 30, 2025 | 0.113 |
| March 31, 2025 | 0.073 |
| December 31, 2024 | 0.1143 |
| September 30, 2024 | 0.1031 |
| June 30, 2024 | 0.0668 |
| March 31, 2024 | -0.4157 |
| December 31, 2023 | -0.4726 |
| Date | Value |
|---|---|
| September 30, 2023 | -0.3454 |
| June 30, 2023 | -2.058 |
| March 31, 2023 | -11.20 |
| December 31, 2022 | 1.976 |
| September 30, 2022 | 0.31 |
| June 30, 2022 | 0.1076 |
| March 31, 2022 | 0.0522 |
| December 31, 2021 | 0.0578 |
| September 30, 2021 | 0.0366 |
| June 30, 2021 | 0.0076 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 32.12M |
| Total Liabilities (Quarterly) | 28.58M |
| Shareholders Equity (Quarterly) | 3.536M |
| Current Ratio | 1.110 |
| Net Debt Paydown Yield | -20.39% |